Background/Aims: Splicing CYP19 gene variants causing aromatase deficiency in 46,XX disorder of sexual development (DSD) patients have been reported in a few cases. A misbalance between normal and aberrant splicing variants was proposed to explain spontaneous pubertal breast development but an incomplete sex maturation progress. The aim of this study was to functionally characterize a novel CYP19A1 intronic homozygote mutation (IVS9+5G>A) in a 46,XX DSD girl presenting spontaneous breast development and primary amenorrhea, and to evaluate similar splicing variant expression in normal steroidogenic tissues. Methods: Genomic DNA analysis, splicing prediction programs, splicing assays, and in vitro protein expression and enzyme activity analyses were carried out. CYP19A1 mRNA expression in human steroidogenic tissues was also studied. Results: A novel IVS9+5G>A homozygote mutation was found. In silico analysis predicts the disappearance of the splicing donor site in intron 9, confirmed by patient peripheral leukocyte cP450arom and in vitro studies. Protein analysis showed a shorter and inactive protein. The intron 9 transcript variant was also found in human steroidogenic tissues. Conclusions: The mutation IVS9+5G>A generates a splicing variant that includes intron 9 which is also present in normal human steroidogenic tissues, suggesting that a misbalance between normal and aberrant splicing variants might occur in target tissues, explaining the clinical phenotype in the affected patient.

Keywords:
Aromatase deficiency, Mutation, CYP19A1, Steroidogenic tissues, Splicing
1.
Means GD, Mahendroo MS, Corbin CJ, Mathis JM, Powell FE, Mendelson CR, Simpson ER: Structural analysis of the gene encoding human aromatase cytochrome P-450, the enzyme responsible for estrogen biosynthesis. J Biol Chem 1989;264:19385-19391.
2.
Santen RJ, Brodie H, Simpson ER, Siiteri PK, Brodie A: History of aromatase: saga of an important biological mediator and therapeutic target. Endocr Rev 2009;30:343-375.
3.
Bulun SE, Sebastian S, Takayama K, Suzuki T, Sasano H, Shozu M: The human CYP19 (aromatase P450) gene: update on physiologic roles and genomic organization of promoters. J Steroid Biochem Mol Biol 2003;86:219-224.
4.
Shozu M, Akasofu K, Harada T, Kubota Y: A new cause of female pseudohermaphroditism: placental aromatase deficiency. J Clin Endocrinol Metab 1991;72:560-566.
5.
Belgorosky A, Guercio G, Pepe C, Saraco N, Rivarola MA: Genetic and clinical spectrum of aromatase deficiency in infancy, childhood and adolescence. Horm Res 2009;72:321-330.
6.
Hauri-Hohl A, Meyer-Böni M, Lang-Muritano M, Hauri-Hohl M, Schoenle EJ, Biason-Lauber A: Aromatase deficiency owing to a functional variant in the placenta promoter and a novel missense mutation in the CYP19A1 gene. Clin Endocrinol (Oxf) 2011;75:39-43.
7.
Verma N, Jain V, Birla S, Jain R, Sharma A: Growth and hormonal profile from birth to adolescence of a girl with aromatase deficiency. J Pediatr Endocrinol Metab 2012;25:1185-1190.
8.
Ludwikowski B, Heger S, Datz N, Richter-Unruh A, González R: Aromatase deficiency: rare cause of virilization. Eur J Pediatr Surg 2013;23:418-422.
9.
Baykan EK, Erdoğan M, Özen S, Darcan Ş, Saygılı LF: Aromatase deficiency, a rare syndrome: case report. J Clin Res Pediatr Endocrinol 2013;5:129-132, erratum in J Clin Res Pediatr Endocrinol 2013;5:216.
10.
Gagliardi L, Scott HS, Feng J, Torpy DJ: A case of aromatase deficiency due to a novel CYP19A1 mutation. BMC Endocr Disord 2014;14:16.
11.
Bouchoucha N, Samara-Boustani D, Pandey AV, Bony-Trifunovic H, Hofer G, Aigrain Y, Polak M, Flück CE: Characterization of a novel CYP19A1 (aromatase) R192H mutation causing virilization of a 46,XX newborn, undervirilization of the 46,XY brother, but no virilization of the mother during pregnancies. Mol Cell Endocrinol 2014;390:8-17.
12.
Yamada-Mouri N, Hirata S, Kato J, Hoshi K: Expression and distribution of cortical type aromatase mRNA variant in the adult rat brain. J Steroid Biochem Mol Biol 1997;60:325-329.
13.
Roselli CE, Abdelgadir SE, Rønnekleiv OK, Klosterman SA: Anatomic distribution and regulation of aromatase gene expression in the rat brain. Biol Reprod 1998;58:79-87.
14.
Levallet J, Mittre H, Delarue B, Carreau S: Alternative splicing events in the coding region of the cytochrome P450 aromatase gene in male rat germ cells. J Mol Endocrinol 1998;20:305-312.
15.
Delarue B, Breard E, Mittre H, Leymarie P: Expression of two aromatase cDNAs in various rabbit tissues. J Steroid Biochem Mol Biol 1998;64:113-119.
16.
Abdelgadir SE, Roselli CE, Choate JV, Resko JA: Distribution of aromatase cytochrome P450 messenger ribonucleic acid in adult rhesus monkey brains. Biol Reprod 1997;57:772-777.
17.
Pereyra-Martinez AC, Roselli CE, Stadelman HL, Resko JA: Cytochrome P450 aromatase in testis and epididymis of male rhesus monkeys. Endocrine 2001;16:15-19.
18.
Lephart ED, Peterson KG, Noble JF, George FW, McPhaul MJ: The structure of cDNA clones encoding the aromatase P-450 isolated from a rat Leydig cell tumor line demonstrates differential processing of aromatase mRNA in rat ovary and a neoplastic cell line. Mol Cell Endocrinol 1990;70:31-40.
19.
Fukada S, Tanaka M, Matsuyama M, Kobayashi D, Nagahama Y: Isolation, characterization, and expression of cDNAs encoding the Medaka (Oryzias latipes) ovarian follicle cytochrome P-450 aromatase. Mol Reprod Dev 1996;45:285-290.
20.
Hanoux V, Bouraima H, Mittre H, Féral C, Benhaïm A: Differential regulation of two 3′ end variants of P450 aromatase transcripts and of a new truncated aromatase protein in rabbit preovulatory granulosa cells. Endocrinology 2003;144:4790-4798.
21.
Pepe CM, Saraco NI, Baquedano MS, Guercio G, Vaiani E, Marino R, Pandey AV, Flück CE, Rivarola MA, Belgorosky A: The cytochrome P450 aromatase lacking exon 5 is associated with a phenotype of nonclassic aromatase deficiency and is also present in normal human steroidogenic tissues. Clin Endocrinol (Oxf) 2007;67:698-705.
22.
Greulich WW, Pyle SI: Radiographic Atlas of Skeletal Development of the Hand and Wrist. Stanford, Stanford University Press, 1959.
23.
Belgorosky A, Pepe C, Marino R, Guercio G, Saraco N, Vaiani E, Rivarola MA: Hypothalamic-pituitary-ovarian axis during infancy, early and late prepuberty in an aromatase-deficient girl who is a compound heterocygote for two new point mutations of the CYP19 gene. J Clin Endocrinol Metab 2003;88:5127-5131.
24.
Tools for Prediction and Analysis of Protein-Coding Gene Structure. Istituto di Tecnologie Biomediche Avanzate. http://bioinfo4.itb.cnr.it/∼webgene/wwwspliceview.html.
25.
Yeo G, Burge CB: Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals; in Vingron M, Istrail S, Pevzner P, Waterman M (eds): RECOMB 2003: Proceedings of the Seventh Annual International Conference on Research in Computational Molecular Biology. New York, ACM, 2003, pp 322-331.
26.
Brunak S, Engelbrecht J, Knudsen S: Prediction of human mRNA donor and acceptor sites from the DNA sequence. J Mol Biol 1991;220:49-65.
27.
Reese MG, Eeckman FH, Kulp D, et al: Improved splice site detection in Genie. J Comput Biol 1997;4:311-323.
28.
Cartegni L, Wang J, Zhu Z, et al: ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acids Res 2003;31:3568-3571.
29.
Harada N, Ogawa H, Shozu M, Yamada K: Genetic studies to characterize the origin of the mutation in placental aromatase deficiency. Am J Hum Genet 1992;51:666-672.
30.
Mullis PE, Yoshimura N, Kuhlmann B, Lippuner K, Jaeger P, Harada H: Aromatase deficiency in a female who is compound heterozygote for two new point mutations in the P450arom gene: impact of estrogens on hypergonadotropic hypogonadism, multicystic ovaries, and bone densitometry in childhood. J Clin Endocrinol Metab 1997;82:1739-1745.
31.
Guercio G, Di Palma MI, Pepe C, Saraco NI, Prieto M, Saure C, Mazza C, Rivarola MA, Belgorosky A: Metformin, estrogen replacement therapy and gonadotropin inhibition fail to improve insulin sensitivity in a girl with aromatase deficiency. Horm Res 2009;72:370-376.
32.
Burckhardt MA, Obmann V, Wolf R, Janner M, Flück CE, Mullis PE: Ovarian and uterine development and hormonal feedback mechanism in a 46 XX patient with CYP19A1 deficiency under low dose estrogen replacement. Gynecol Endocrinol 2015;14:1-6.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.